early
-
Alzheimer’s & Dementia Care
U.S. FDA Approves Leqembi Iqlik Subcutaneous Autoinjector for Early Alzheimer’s Disease Maintenance Dosing
The U.S. Food and Drug Administration (FDA) has announced the approval of Leqembi Iqlik (lecanemab-irmb), an innovative under-the-skin autoinjector formulation…
Read More » -
Alzheimer’s & Dementia Care
Kisunla approval offers new option for early Alzheimer’s in Europe
The European Commission has granted marketing authorization for Eli Lilly’s monthly infusion therapy, Kisunla (donanemab), targeting adults with early symptomatic…
Read More » -
Senior Care & Aging in Place
The Evolving Landscape of Dementia Screening: Navigating Modern Cognitive Assessments for Early Detection and Proactive Care
Initial signs of cognitive decline—a mother forgetting a recent conversation, a spouse disoriented in a familiar grocery store—often trigger immediate…
Read More » -
Alzheimer’s & Dementia Care
Blarcamesine Demonstrates Sustained Efficacy Over Three Years in Early Alzheimer’s Disease, Offering Hope for Disease Modification
Copenhagen, Denmark – In a significant development for Alzheimer’s disease research, Anavex Life Sciences has announced that the therapeutic benefits…
Read More » -
Alzheimer’s & Dementia Care
FDA Reviews Expanded Approval for Leqembi Iqlik: Subcutaneous Option for Early Alzheimer’s Treatment Initiation
The U.S. Food and Drug Administration (FDA) is currently reviewing a supplemental Biologics License Application (sBLA) seeking expanded approval for…
Read More »